Drug Trial Radar · NCT07857135
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Oct 3, 2026
Primary completion
Feb 3, 2029
Study completion Aug 3, 2029
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, open-label, dose-escalation, dose-expansion, and cohort-expansion first-in-human Phase 1/2 study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of SYS6088 in patients with advanced/metastatic solid tumors.
Conditions
- Advanced/Metastatic Solid Tumors
Interventions
SYS6088Drug
SYS6088, administered per protocol.
RegorafenibDrug
Regorafenib, administered per protocol.
IvonescimabDrug
Ivonescimab, administered per protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The occurrence and frequency of Dose-limiting toxicities (DLTs) DLTs during the studyTime frame: Up to 90 days after last administration
- The occurrence and frequency of Treatment-emergent adverse events (TEAEs)Time frame: Up to 90 days after last administration
- The maximum tolerated dose (MTD) of SYS6088 (MTD, if any)Time frame: Up to approximately 18 weeks after the first participant is enrolled
- The recommended Phase 2 dose (RP2D) of SYS6088Time frame: Up to approximately 36 weeks after the first participant is enrolled
- Objective remission rate (ORR) assessed by the investigator according to RECIST v1.1Time frame: Up to approximately 3 years
- The occurrence and frequency of TEAEsTime frame: Up to 90 days after last administration
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.